Some La Roche-Posay, Proactiv and Walgreens acne treatments recalled due to benzene levels
U.S. health officials are asking retailers to pull a small number of acne creams from their store shelves after government testing found they contain slightly elevated levels of a chemical associated with cancer.
The Food and Drug Administration said several lots of six products containing benzoyl peroxide are being recalled, including Walgreens Acne Control Cleanser, Proactiv Skin Smoothing Exfoliator and La Roche-Posay Effaclar Duo Dual Action Acne Treatment. The full list and lot numbers was posted online Tuesday.
The FDA stressed consumers face little risk from the products.
'Even with daily use of these products for decades, the risk of a person developing cancer because of exposure to benzene found in these products is very low,' the agency stated.
All of the products contain benzene, a chemical component of crude oil, gas and cigarette smoke. Prolonged exposure to high levels can cause leukemia and other cancers.
The recalls announced this week apply to stores selling the items. FDA officials said consumers don't need to take any specific action.
The FDA identified the six products after testing 95 acne treatment products. The agency's review was prompted by testing reports from private laboratories about excess benzene levels in a number of acne products.
In recent years a variety of other products have been recalled over benzene levels, including hand sanitizers, aerosols and sunscreens.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Forbes
26 minutes ago
- Forbes
Talk Is Cheap: Now Trump Must Deliver On His Healthcare Promises
President Donald Trump, accompanied by Health and Human Services Secretary Robert F. Kennedy Jr. ... More (R), holds up an executive order aimed at reducing the cost of prescription drugs and pharmaceuticals by 30% to 80% during an event in the Roosevelt Room of the White House on May 12, 2025, in Washington, D.C. President Donald Trump has made big promises about fixing American healthcare. Now comes the moment that separates talk from action. With the 2026 midterms fast approaching and congressional attention soon shifting to electoral strategy, the window for legislative results is closing quickly. This summer will determine whether the administration turns promises into policy or lets the opportunity slip away. Trump and his handpicked healthcare leaders — HHS Secretary Robert F. Kennedy Jr. and FDA Commissioner Dr. Marty Makary — have identified three major priorities: lowering drug prices, reversing chronic disease and unleashing generative AI. Each one, if achieved, would save tens of thousands of lives and reduce costs. But promises are easy. Real change requires political will and congressional action. Here are three tests that Americans can use to gauge whether the Trump administration succeeds or fails in delivering on its healthcare agenda. Americans pay two to four times more for prescription drugs than citizens in other wealthy nations. This price gap has persisted for more than 20 years and continues to widen as pharmaceutical companies launch new medications with average list prices exceeding $370,000 per year. Today, nearly 30% of U.S. prescriptions go unfilled due to cost, leaving millions without the medications they need. One key reason for the disparity is a 2003 law that prohibits Medicare from negotiating prices directly with drug manufacturers. Although the Inflation Reduction Act of 2022 granted limited negotiation rights, the initial round of price reductions did little to close the gap with other high-income nations. President Trump has repeatedly promised to change that. In his first term, and again in May 2025, he condemned foreign 'free riders,' promising, 'The United States will no longer subsidize the healthcare of foreign countries and will no longer tolerate profiteering and price gouging.' To support these commitments, the president signed an executive order titled 'Delivering Most-Favored-Nation (MFN) Prescription Drug Pricing to American Patients.' The order directs HHS to develop and communicate MFN price targets to pharmaceutical manufacturers, with the hope that they will voluntarily align U.S. drug prices with those in other developed nations. Should manufacturers fail to make significant progress toward these targets, the administration said it plans to pursue additional measures, such as facilitating drug importation and imposing tariffs. However, implementing these measures will most likely require congressional legislation and will encounter substantial legal and political challenges. The pharmaceutical industry knows that without congressional action, there is no way for the president to force them to lower prices. And they are likely to continue to appeal to Americans by arguing that lower prices will restrict innovation and lifesaving drug development. But the truth about drug 'innovation' is in the numbers: According to a study by America's Health Insurance Plans, seven out of 10 of the largest pharmaceutical companies spend more on sales and marketing than on research and development. And if drugmakers want to invest more in R&D, they can start by requiring peer nations to pay their fair share — rather than depending so heavily on U.S. patients to foot the bill. If Congress fails to act, the president has other tools at his disposal. One effective step would be for the FDA to redefine 'drug shortages' to include medications priced beyond the reach of most Americans. That change would enable compounding pharmacies to produce lower-cost alternatives just as they did recently with GLP-1 weight-loss injections. If no action is taken, however, and Americans continue paying more than twice as much as citizens in other wealthy nations, the administration will fail this crucial test. Obesity has become a leading health threat in the United States, surpassing smoking and opioid addiction as a cause of death. Since 1980, adult obesity rates have surged from 15% to over 40%, contributing significantly to chronic diseases, including type 2 diabetes, heart disease and multiple types of cancers. A major driver of this epidemic is the widespread consumption of ultra-processed foods: products high in added sugar, unhealthy fats and artificial additives. These foods are engineered to be hyper-palatable and calorie-dense, promoting overconsumption and, in some cases, addictive eating behaviors. RFK Jr. has publicly condemned artificial additives as 'poison' and spotlighted their impact on children's health. In May 2025, he led the release of the White House's Make America Healthy Again (MAHA) report, which identifies ultra-processed foods, chemical exposures, lack of exercise and excessive prescription drug use as primary contributors to America's chronic disease epidemic. But while the report raises valid concerns, it has yet to produce concrete reforms. To move from rhetoric to results, the administration will need to implement tangible policies. Here are three approaches (from least difficult to most) that, if enacted, would signify meaningful progress: These measures will doubtlessly face fierce opposition from the food and agriculture industries. But if the Trump administration and Congress manage to enact even one of these options — or an equivalent reform — they can claim success. If, instead, they preserve the status quo, leaving Americans to decipher nutritional fine print on the back of the box, obesity will continue to rise, and the administration will have failed. The Trump administration has signaled a strong commitment to using generative AI across various industries, including healthcare. At the AI Action Summit in Paris, Vice President JD Vance made the administration's agenda clear: 'I'm not here this morning to talk about AI safety ... I'm here to talk about AI opportunity.' FDA Commissioner Dr. Marty Makary has echoed that message with internal action. After an AI-assisted scientific review pilot program, he announced plans to integrate generative AI across all FDA centers by June 30. But internal efficiency alone won't improve the nation's health. The real test is whether the administration will help develop and approve GenAI tools that expand clinical access, improve outcomes and reduce costs. To these ends, generative AI holds enormous promise: These breakthroughs aren't theoretical. They're achievable. But they won't happen unless federal leaders facilitate broad adoption. That will require investing in innovation. The NIH must provide funding for next-generation GenAI tools designed for patient empowerment, and the FDA will need to facilitate approval for broad implementation. That will require modernizing current regulations. The FDA's approval process wasn't built for probabilistic AI models that rely on continuous application training and include patient-provided prompts. Americans need a new, fit-for-purpose framework that protects patients without paralyzing progress. Most important, federal leaders must abandon the illusion of zero risk. If American healthcare were delivering superior clinical outcomes, managing chronic disease effectively and keeping patients safe, that would be one thing. But medical care in the United States is far from that reality. Hundreds of thousands of Americans die annually from poorly controlled chronic diseases, medical errors and misdiagnoses. If generative AI technology remains confined to billing support and back-office automation, the opportunity to transform American healthcare will be lost. And the administration will have failed to deliver on this promise. When I teach strategy at Stanford's Graduate School of Business, I tell students that the best leaders focus on a few high-priority goals with clear definitions of success — and a refusal to accept failure. Based on the administration's own words, grading the administration on these three healthcare tests will fulfill those criteria. However, with Labor Day just months away, the window for action will soon close. The time for presidential action is now.
Yahoo
10 hours ago
- Yahoo
Baby swabs and nasal swabs recalled for possible fungus in swab parts
Swabs for teething babies and adult noses have been recalled because they might have a microbial contamination 'identified as fungi in cotton swab components.' That's what manufacturer Church & Dwight said in its notice announcing the recall of Orajel Baby Teething Swabs, Zicam Cold Remedy Nasal Swabs and Zicam Nasal AllClear Swabs from stores across the United States, including Puerto Rico. The lots and expiration dates involved? All. READ MORE: Recalled UTI drug could have deadly microbial contamination Swabs with a microbial contamination can cause 'serious and life-threatening blood infections in users whose nasal mucosa may be compromised due to inflammation and mechanical injurie,' the recall notice states. 'The risk is highest (potentially severe or life-threatening) among children and individuals with compromised immune systems or other underlying medical conditions.' ▪ Zicam Cold Remedy Nasal Swabs carry UPC No. 732216301205. ▪ Zicam Nasal AllClear Swabs, which were discontinued in December, carry UPC No. 732216301656. ▪ Orajel baby swabs carry UPC No. 310310400002. If you have the swabs, throw them in the trash or, for a refund, reach out go Church & Dwight either online or by calling 800-981-4710. Questions can be directed to that phone number, 9 a.m. to 5 p.m., Monday through Friday. If you think you or your baby is having a medical issue caused by these swabs, go see a medical professional. Then, notify the FDA's MedWatch Adverse Event Program, either by filling out a form online or by requesting a reporting form at 800-332-1088. Then, third, call Church & Dwight.
Miami Herald
11 hours ago
- Miami Herald
Salmonella recall of 20 million eggs from Walmart, Safeway, Ralphs, among others
Another salmonella outbreak caused the recall of 1.7 million dozen eggs — meaning roughly more than 20 million less eggs to fry — and has sickened people in seven states. The aforementioned eggs were distributed to Walmart, Safeway, chains owned by Kroger and various other independent and chain supermarkets. Hilmar, California's August Egg Company, a division of Gemperle Enterprises, produced the eggs and issued the recall Friday. 'August Egg Company is not selling fresh shell eggs at this time,' the company-written, FDA-posted recall notice said. 'Our firm has voluntarily been diverting eggs to an egg-breaking plant for over 30 days, which pasteurizes the eggs and kills any potential foodborne pathogens.' READ MORE: Public health alert: Deadly E. coli found in beef sent to Whole Foods stores What eggs have been recalled? Packaging for the recalled eggs will have plant code P-6562 or CA5330 with the Julian Dates between 32 to 126. The eggs that went to Walmart stores had sell by dates from March 4 through June 19. Other retailers got eggs with 'sell by dates' from March 4 through June 4. August Egg says these eggs went to stores in California, Washington, Illinois, Nevada, Arizona, Wyoming, New Mexico, Nebraska, and Indiana. The recall section of Walmart's website says this also involves its stores in Alaska, Colorado, Hawaii, Iowa, Idaho, Kansas, Michigan, Montana, North Dakota, Ohio, Oklahoma, Oregon, Texas and Wisconsin. ▪ Marketside (a Walmart store brand): Organic Large Cage Free Brown Eggs in cartons of 12 and 18; Large Cage Free Brown Eggs in cartons of 12 and 18. ▪ First Street (a Smart & Final house brand): Cage Free Large Brown loose eggs. ▪ Clover: Organic Large Brown Eggs, one dozen. ▪ Nulaid: One dozen Medium Brown Cage Free, one dozen Jumbo Brown Cage Free. ▪ O Organics: Cage Free Large Brown, six eggs; and Large Brown, 12 and 18 eggs. This brand will be found at Safeway and other Albertson's-owned stores. ▪ Raley's (store brand): Large Cage Free Brown, 12 eggs: Organic Large Cage Free Brown, 12 and 18 eggs. ▪ Simple Truth: Cage Free Large Brown and Medium Brown 18 eggs. This brand will be found at Food 4 Less, Ralphs and other Kroger-owned chains. ▪ Sun Harvest: Organic Large Cage Free Brown Eggs in cartons of 12 and 18. ▪ Sunnyside: Organic Large Cage Free Brown Eggs in cartons of 12 and 18; and Large Cage Free Brown Eggs in cartons of 12 and 18. What's up with the salmonella outbreak? Saturday's outbreak update from the Centers for Disease Control and Prevention says 79 people have been sickened in this outbreak with 21 hospitalizations. Of those 79, 63 are in California. The remaining 16 break down as Nevada and Washington (four each); Arizona, three; Nebraska and New Jersey (two each); and Kentucky, one. Salmonella outbreaks tend to be very undercounted because most people recover without medical attention. What is salmonella? The CDC estimates about 1.35 million people in the United States will get salmonella each year. Of that number, 26,400 will be hospitalized, usually driven to the hospital by bloody diarrhea, and 420 will die. Usually, salmonella just means a few days of diarrhea, vomiting, fever and stomachaches. What you should do now If you have any of the recalled eggs listed above, return them to the store for a refund or throw them deep into the garbage. If you have any questions about the recalls, call August Farms at 800-710-2554, noon to 8 p.m., Eastern time.
